Bijal Shah

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma”.

Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Blood Cancer Discovery(2024)10.1158/2643-3230.bcd-23-0056

N/A

0.557DataRank · unranked

40 citations

Sae Bom Lee, Michael D. Jain, Biwei Cao, Xuefeng Wang, Kai Rejeski +28 more

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel

Cancer Medicine(2021)10.1002/cam4.3664

N/A

0.538DataRank · unranked

35 citations

Reena Jayani, Aaron Collier, Nathaly Irizarry‐Arroyo, Yvelise Rodriguez, Michael D. Jain +17 more

Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Blood Cancer Discovery(2023)10.1158/2643-3230.bcd-23-0106

N/A

0.538DataRank · unranked

35 citations

Pu Zhang, Jacob Stauber, Ibrahim Aldoss, Adam S. Sperling, Lachelle D. Weeks +30 more

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts

Blood Advances(2025)10.1182/bloodadvances.2024015441

N/A

0.533DataRank · unranked

34 citations

Ibrahim Aldoss, Daniel J. DeAngelo, Marina Konopleva, Jessica Leonard, Aaron C. Logan +5 more

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025017526

N/A

0.267DataRank · unranked

3 citations

Chenyu Lin, David Nemirovsky, Sean Devlin, Kai Rejeski, Kevin J. Curran +43 more

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011807

N/A

0.241DataRank · unranked

4 citations

Michael D. Jain, Meghan Menges, Ling Cen, Jerald Noble, Reginald Atkins +20 more

Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.09.013

N/A

0.241DataRank · unranked

4 citations

Anna Barata, Xiaoyin Li, Nathaly Irizarry‐Arroyo, Michael D. Jain, Taylor Welniak +19 more

Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma

Research Square(2025)10.21203/rs.3.rs-6306816/v1

N/A

0.104DataRank · unranked

1 citations

Rafael Renatino Canevarolo, Praneeth Sudalagunta, Mark B. Meads, Maria João Silva, Xiaohong Zhao +29 more

The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

American Journal of Hematology(2023)10.1002/ajh.27056

N/A

0DataRank · unranked

48 citations

Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni +15 more

C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models

Journal of Clinical Investigation(2024)10.1172/jci177429

N/A

0DataRank · unranked

18 citations

Kimberly Gómez, Yan Chen, Heather N. Allen, Sara Hestehave, Erick J. Rodríguez‐Palma +19 more

Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.03.023

N/A

0DataRank · unranked

44 citations

Anna Barata, Jennifer M. Logue, Anuhya Kommalapati, Kelly A. Hyland, Ashley M. Nelson +15 more

The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

Blood(2022)10.1182/blood.2022016194

N/A

0DataRank · unranked

88 citations

Michael Slade, Hagop M. Kantarjian, Julio Alvarenga, Ibrahim Aldoss, Kahee A. Mohammed +16 more

Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.05.018

N/A

0DataRank · unranked

14 citations

Ariel Perez Perez, Christina A. Bachmeier, Rahul Mhaskar, Julio C. Chávez, Bijal Shah +7 more

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy

International Journal of Radiation Oncology*Biology*Physics(2021)10.1016/j.ijrobp.2021.06.038

N/A

0DataRank · unranked

53 citations

Timothy J. Robinson, Austin J. Sim, Xuefeng Wang, Biwei Cao, Julio C. Chávez +11 more

Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma

Transplantation and Cellular Therapy(2020)10.1016/j.jtct.2020.12.025

N/A

0DataRank · unranked

10 citations

Ambuj Kumar, Hamza Hashmi, Franco Garcia, Constantine Logothetis, Alicia Darwin +14 more